Key Facts – Women's Health at Work & WMSDsWMSDs are Australia's #1 workplace injury, costing the economy more than $55 billion annually in ...

Interstitial Lung Disease (ILD): In the PHAROS trial, 1 patient (1%) receiving MEKTOVI with BRAFTOVI developed pneumonitis. Assess new or progressive unexplained pulmonary symptoms or findings for ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced landmark results demonstrating ...

Dear: I’ve read that the Social Security Administration offers a lump-sum payment to new retirees who need some extra cash. I ...

Positive results from the DESTINY-Breast05 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) demonstrated a highly statistically significant and clinically meaningful improvement in ...

Positive results from the DESTINY-Breast11 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) followed by paclitaxel, trastuzumab and pertuzumab (THP) in the neoadjuvant setting ...

Introduction Therapeutic exercise has been used to improve cancer-related dysfunction. Recent studies suggest that exercise after chemotherapy can improve cancer-related cognitive impairment. However, ...